ICI 89406

ICI 89406 is a selective β1 adrenergic receptor antagonist amenable to labelling with positron emitters, for PET[1][2].

Signaling Pathways >> GPCR/G Protein >> Adrenergic Receptor

Research Areas >> Metabolic Disease

Animal Model: Rats[2]. Dosage: 0.6, 5 or 50 mg/kg. Administration: Orally (5 or 50 mg/kg), i.p. (5 mg/kg), i.v. 0.6 (0.6 mg/kg) (Pharmacokinetic Analysis). Result: Following oral administration, the dose of 5 mg/kg urinary and faecal excretion accounted for 5.8 + 0.7% and 96.4 + 2.1%. The dose of 50 mg/kg urinary and faecal excretion accounted for 14.0 + 4.0% and 78.4 + 2.4%. The proportions of unchanged drug and metabolites in urine were independent of the dose. The unchanged drug accounted for 81.6% of the faecal components after a dose of 5 mg/kg but this was reduced to 47.8%.

[1]. Marilyn P Law, et al. Are [O-methyl-11C]derivatives of ICI 89,406 beta1-adrenoceptor selective radioligands suitable for PET? Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):174-85.

[2]. B Costall, et al. Changes in dopamine receptor status after denervation or chronic receptor stimulation [proceedings]. Br J Pharmacol. 1979 Jul;66(3):492P-493P.